Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carboxynaphthol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 1.00 |
| ▸ | WDR5 | P61964 | 1/20 | 0.68 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.60 |
| ▸ | CFTR | P13569 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | ATIC | P31939 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carboxynaphthol SCHEMBL25244 | 1.00 | LDHA (1.00) | LDHAWDR5NR4A1NR4A2NR4A3 | |
| Carboxynaphthol SCHEMBL2099330 | 1.00 | LDHA (1.00) | LDHAWDR5NR4A1NR4A2NR4A3 | |
| Carboxynaphthol SCHEMBL7257660 | 0.98 | LDHA (0.96) | LDHAWDR5NR4A1NR4A2NR4A3 | |
| Carboxynaphthol SCHEMBL28259598 | 0.98 | LDHA (0.96) | LDHAWDR5NR4A1NR4A2NR4A3 | |
| Carboxynaphthol SCHEMBL27673953 | 0.98 | LDHA (0.96) | LDHAWDR5NR4A1NR4A2NR4A3 | |
| Carboxynaphthol SCHEMBL25371193 | 0.98 | LDHA (0.96) | LDHAWDR5NR4A1NR4A2NR4A3 | |
| Carboxynaphthol SCHEMBL25369919 | 0.98 | LDHA (0.96) | LDHAWDR5NR4A1NR4A2NR4A3 | |
| Carboxynaphthol SCHEMBL1458046 | 0.98 | LDHA (0.96) | LDHAWDR5NR4A1NR4A2NR4A3 | |
| Carboxynaphthol SCHEMBL10943009 | 0.98 | LDHA (0.96) | LDHAWDR5NR4A1NR4A2NR4A3 | |
| Carboxynaphthol SCHEMBL5964608 | 0.98 | LDHA (0.96) | LDHAWDR5NR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9084799-B2 | Inhaled combination therapy | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-20130203716-A1 | Inhaled Combination Therapy | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-8431553-B2 | Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-8426393-B2 | Inhaled combination therapy | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-04-23 | — | — | US | disclosed |
| CN-102526074-A | Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases | ARGENTA DISCOVERY LTD | 2012-07-04 | — | — | CN | disclosed |
| US-20100324002-A1 | Inhaled combination therapy | FOX JUSTIAN CRAIG | 2010-12-23 | — | — | US | disclosed |
| EP-1845994-B1 | COMBINATION OF METHYLXANTHINE COMPOUNDS AND STEROIDS TO TREAT CHRONIC RESPIRATORY DISEASES | ARGENTA DISCOVERY LTD (GB) | 2009-01-21 | — | — | EP | disclosed |
| US-20080318913-A1 | Combination of Methylxanthine Compounds and Steroids to Treat Chronic Respiratory Diseases | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080318912-A1 | Medicaments for Treating Chronic Respiratory Disease | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| EP-1845994-A1 | COMBINATION OF METHYLXANTHINE COMPOUNDS AND STEROIDS TO TREAT CHRONIC RESPIRATORY DISEASES | Argenta Discovery Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1773342-A1 | MEDICAMENTS FOR TREATING CHRONIC RESPIRATORY DISEASE | Argenta Discovery Limited (GB) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006085102-A1 | COMBINATION OF METHYLXANTHINE COMPOUNDS AND STEROIDS TO TREAT CHRONIC RESPIRATORY DISEASES | ARGENTA DISCOVERY LIMITED (GB) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006013359-A1 | MEDICAMENTS FOR TREATING CHRONIC RESPIRATORY DISEASE | ARGENTA DISCOVERY LIMITED (GB) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203716-A1 | Inhaled Combination Therapy | CYP11B2, CYP11B1, TBXA2R | LDHA 3131/4885WDR5 2933/4885NR4A1 299/4885 |
| US-20080318913-A1 | Combination of Methylxanthine Compounds and Steroids to Treat Chronic Respiratory Diseases | CYP11B2, CYP11B1, CYP27A1 | LDHA 2169/4885WDR5 3667/4885NR4A1 171/4885 |
| US-20080318912-A1 | Medicaments for Treating Chronic Respiratory Disease | NR3C2, MRGPRX2, EPX | LDHA 384/4885WDR5 3509/4885NR4A1 1058/4885 |
| US-20100324002-A1 | Inhaled combination therapy | CYP11B2, CYP11B1, TBXA2R | LDHA 3131/4885WDR5 2933/4885NR4A1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.